key: cord-1026277-tguqyppj
authors: Vieira, Matheus; Maalouf, Georgina; Hasan, Milena; Le Joncour, Alexandre; Karkeni, Esma; Idir, Merwan; Amelin, Damien; Salem, Joe-Elie; Gougis, Paul; Lacorte, Jean-Marc; Biard, Lucie; Benveniste, Olivier; Cacoub, Patrice; Saadoun, David; Allenbach, Yves
title: Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on “Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome” by Quartuccio et al. Joint Bone Spine. 2020;87:191-93
date: 2020-09-17
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2020.09.006
sha: fafb6272ab70e2fc8345a2c5e49294ebe84fe45e
doc_id: 1026277
cord_uid: tguqyppj

nan

downstream inflammation to prevent catastrophic syndrome'. As hightlighted by Quartuccio et al., using biomarkers to early identify patients at higher risk of clinical deterioration is crucial in choosing a suitable candidate for anti-cytokine therapy [1] . The timing and choice of the therapy is also key, since immunosuppressant strategies could impair the antiviral response.

Serum cytokine levels have been associated with disease severity, but not much with short-term outcomes. To address this issue, we conducted a prospective cohort encompassing 109 COVID-19 adult non-ICU inpatients (NCT04320017).

Data was collected at hospital admission, and patients were categorized at day 14 (D14) according to the occurrence of death and/or ICU transfer. Inactivated plasma samples were tested for IL-1β, IL-2, IL-4, IL-5, IFNγ, IL-6, IL-8, IL-10, IL-12p70, IL-22, IFN-β and TNF using high sensitivity kits. Patients's baseline features and cytokine levels are presented in Table 1 and Table 2 , respectively. At D14, 22.1% of patients were transferred to the ICU or died. Patients in this group had significantly higher baseline levels of IL-6, IL-8, TNF and IL-10. Those with baseline high viral load presented significantly higher levels of IL-10 (17.75 vs. 8 .39 pg/ml, p < 0.01), IFN-ɣ (3.14 vs. 1.04 pg/ml, p < 0.05) and TNF (24.22 vs. 18.1 pg/ml, p < 0.05).

The immune phenotype of severe and critically ill COVID-19 patients is characterized by an impaired type I IFN response and hyper-inflammation [2, 3] . In this regard, high baseline cytokine levels might be important prognostic biomarkers of the potentially lethal cytokine wave [2] .

Herein, we evidenced that baseline inflammatory cytokines, notably IL-6, IL-8 and TNF, but also IL-10, correlate well with short-term clinical outcomes. This highlights not only the importance of their measurement as potential prognostic tools, but also provides crucial insights on timing and targets for immunosuppressant strategies. IL-6 is the most studied cytokine and Page 3 of 8 J o u r n a l P r e -p r o o f 3 its blockade was shown to partially rescue immune dysregulation both in vitro and in vivo [4] .

Beyond, prospective observational data shows promising results [5] , while results from several randomized clinical trials are eagerly awaited. Based on our findings and on others studies [6] [7] [8] , another potential target would be TNF [2, 9] . Despite the known deleterious effect in septic shock [1], observational data from inflammatory bowel disease patients on TNF blockers showed interesting results [9] . So far, anti-TNF has received less attention than anti-IL6 in COVID-19.

In conclusion, cytokine profiling at baseline can predict short-term outcomes, and thus could be used to choose proper candidates for directed-targeted therapies. Ongoing randomized clinical trials testing disease-modifying anti-rheumatic drugs will provide important answers, while testing baseline cytokine levels could be considered in patient enrollment.

The authors declare to have no disclosures. 

Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed